The Roles of Biomarker Testing and HRCT in IPF and PPF
Paul Noble, MD, discusses the roles of biomarker testing and HRCT in IPF and PPF.
Video content above is prompted by the following:
- What’s the role of biomarker testing in IPF and PPF and can it be used to differentiate IPF and PPF from other diseases?
- What’s the role of HRCT in identifying patients with IPF or PPF and what’s commonly seen on histopathology?
Recent Videos
Related Content
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021Article
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
